James

James Williams BSc (Hons) PhD MBA

James has broad experience covering executive management of public and private companies, establishment, resourcing and financing start-up companies and hands-on research in molecular and cell biology.

As CEO/MD, James has successfully taken two medical devices to market, in both cases managing a rapid transition of academic research to commercial, revenue generating operations (Argus Biomedical’s artificial cornea and Resonance Health Ltd’s Ferriscan diagnostic for measurement of liver iron content).

James is co-founder, former Executive and current Director of two biotechnology companies involved in drug discovery, delivery and repositioning (iCeutica Group and Dimerix Biosciences Pty Ltd). Both companies are achieving significant milestones including human trials and revenue generation through early commercial contracts and/or technology evaluation agreements with global multi-national companies.

Prior to becoming involved in biotechnology commercialisation with Liddy McCall in 2000, James was a Senior Research Officer at the Western Australian Institute of Medical Research (WAIMR) researching the molecular and cellular biology of cancer. In addition to having numerous publications in leading international journals, he is named as inventor on patents covering a range of disciplines that are being prosecuted as part of Australian company’s technology portfolios. Noteworthy examples are patents describing iCeutica’s core technology for developing nano drugs, and the HLS5 tumour suppressor gene he cloned during post-doctoral studies and which is being commercialised by ASX-listed Biopharmica Ltd.

James is a co-founder and Investment Director of Yuuwa Capital. He has a broad interest in the successful commercialisation of early stage technologies, with a particular focus on those stemming from the Life Sciences.